Alios BioPharma

Alios BioPharma discovers and develops novel therapeutic drugs based on three platform technologies, including: small molecule activators of innate immune antiviral pathways (RNase L activation), phosphate-protected nucleotide prodrug chemistry, and glycoprotein engineering of interferons (Glycoferon™). This complementary set of platform technologies has the potential to generate a wide range of therapeutic products for treating various severe viral infections, such as chronic hepatitis B and C, HIV infection, respiratory viruses (such as pandemic influenza), and emerging viral diseases (such as SARS).